CD7 and acute lymphoblastic leukemia: A Phase I clinical trial (NCT03690011) is under development for the evaluation of CD7-CRISPR-Cas9-edited CD7 CAR T cells treatment of patients with CD7+ T-cell malignancies, including T-ALL.